Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2469 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Misonix Reports Q2 Fiscal 2009 Results

The company also reported the following financial and operational achievements: $0.03 diluted earnings per share and a 5.1% increase in revenue for the three months ended December 31,

Cytomedix appoints new board members

Mr Winzer has served as executive vice president and CFO of Avalon Pharmaceuticals since July 2007. Dr Keith assumed the position of president and COO of Panacea Pharmaceuticals

WorldHeart names new president and CEO

Mr Martin joins WorldHeart from Edwards Lifesciences where he was president of the North American region and corporate vice president since 2004. Previously, Mr Martin was with Cordis,

Amgen wins European approval for blood platelet drug

Nplate may be considered as second line treatment for adult non-splenectomized immune thrombocytopenic purpura patients where surgery is contra-indicated. According to the company, Nplate, the first and only

Orexo signs development agreement for GERD program

During this development work, Orexo will continue negotiations to enter into an appropriate global exclusive licensing agreement including the whole of Orexo’s Ox17 program and related intellectual property.